Lessons from examining the safety of drugs for COVID-19 during pregnancy
The COVID-19 pandemic exposed a critical gap in clinical research through the systematic exclusion of pregnant women from therapeutic trials. Current evidence, though largely observational, supports vaccination as the primary preventive strategy, nirmatrelvir/ritonavir for outpatients at risk of progression, and remdesivir plus corticosteroids for hospitalized patients requiring oxygen supplementation.
Authors
- Elvira Forte (ORCID: https://orcid.org/0000-0002-5555-9122)
- Antonio Riccardo Buonomo (ORCID: https://orcid.org/0000-0002-4378-8366)
- Nicola Schiano Moriello (ORCID: https://orcid.org/0000-0001-8474-4776)
- N Esposito
- Emilia Trucillo
- Isabella Di Filippo
- Ivan Gentile
Institutions
- University of Sannio (IT)
- Ospedale Antonio Cardarelli (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2026-03-09
- DOI
- https://doi.org/10.1080/14740338.2026.2637649
- Primary Topic
- COVID-19 Impact on Reproduction
- Type
- article
- Field-Weighted Citation Impact
- 0.00